Stockscreener 앱 받기
32.15
2.90%
-0.96
시간 외 거래:
32.47
0.32
+1.00%
전일 마감가:
$33.11
열려 있는:
$33.41
하루 거래량:
675.33K
Relative Volume:
0.88
시가총액:
$1.40B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-229.64
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
+0.53%
1개월 성능:
+18.16%
6개월 성능:
+64.96%
1년 성능:
+29.79%
1일 변동 폭
$31.78
$33.68
1주일 범위
$31.78
$33.98
52주 변동 폭
$17.82
$33.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
32.15 | 2.42B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells $4,601,984.80 in Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock - MarketBeat
John F. Paolini Sells 29,325 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighHere's What Happened - MarketBeat
BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen - Defense World
Wedbush Issues Positive Outlook for KNSA Earnings - MarketBeat
Kiniksa Pharmaceuticals surges 11.01% on Arcalyst's market penetration - AInvest
Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High After Earnings Beat - MarketBeat
Equities Analysts Set Expectations for KNSA Q3 Earnings - Defense World
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge - Yahoo Finance
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - Yahoo Finance
Victory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Achieves 52% YoY Growth in Q2 2025, Raises Revenue Guidance - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates - MSN
Kiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration rises - MSN
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... - Yahoo Finance
Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67 - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... By GuruFocus - Investing.com Canada
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High After Strong Earnings - Defense World
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Kiniksa: Jefferies maintains Buy, raises PT to $54 from $45. - AInvest
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results - AInvest
Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals International Q2 2025 Earnings Call Transcript - MarketBeat
Kiniksa Pharmaceuticals Reports Q2 2025 Financial Results with 52% Growth in ARCALYST Revenue and Updates on Clinical Trials - Quiver Quantitative
Kiniksa Crushes Earnings: ARCALYST Sales Jump 52%, Company Raises 2025 Revenue Target to $640M - Stock Titan
Kiniksa Pharmaceuticals Q2 2025 Earnings Preview: $0.22 EPS, $145.21M Revenue Expected - AInvest
Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Buy” by Analysts - Defense World
Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call. - AInvest
Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a shareEarnings Preview - TradingView
Cwm LLC Has $491,000 Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings: Key Financial Results Coming July 29How to Join - Stock Titan
Cerity Partners LLC Boosts Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Ltd. Stock Analysis and ForecastExceptional gains - Autocar Professional
BlackRock, Inc. Significantly Reduces Holdings in Kiniksa Pharmaceuticals International PLC - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Teacher Retirement System of Texas Decreases Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):